| Description |
1 online resource (xvi, 347 pages). |
|
text file |
| Series |
Drug discovery series ; 73
|
|
RSC drug discovery series ; 73.
|
| Bibliography |
Includes bibliographical references and index. |
| Summary |
Anti-fibrotic Drug Discovery is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology. |
| Contents |
TGFß Signalling in Fibrosis; Targeting Integrins in Fibroproliferative Disease; Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor (FXR) Activators; Autotaxin Inhibitors in Fibrosis; Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology; Galectin-3 Involvement in Fibrotic Diseases; The Emerging Role of CXCR4 in IPF; BH3 Mimetic Drugs for Anti-Fibrotic Therapy; Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities; Targeting Fibroblasts in Cancer and Fibrosis |
| Local Note |
eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - North America |
| Subject |
Drug development.
|
|
Drug development. |
|
Drugs -- Design.
|
|
Drugs -- Design. |
| Genre/Form |
Electronic books.
|
|
Electronic books.
|
| Subject |
Medication. |
| Added Author |
Brenneman, Jehrod, editor.
|
|
Iyer, Malliga R, editor.
|
| Other Form: |
Print version: Anti-fibrotic drug discovery 9781788015103 |
| ISBN |
9781788015783 (electronic book) |
|
1788015789 (electronic book) |
|
9781839160516 (electronic book) |
|
1839160519 (electronic book) |
|
9781788015103 |
|
178801510X |
|
